文献速递免疫规划传染病防控与疫情报告

欧洲与北美住院儿童侵袭性肺炎球菌疾病PCV引入后影响与血清型替换相似

Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.
PubMed 文献 · Vaccine · 2021-02-18

该研究重新分析已发表汇总数据,比较不同国家PCV引入前后侵袭性肺炎球菌疾病(IPD)发病率,将住院与门诊IPD分开分析。结果显示美国门诊IPD发病率下降幅度大于住院IPD,分层后美国住院IPD的PCV影响和血清型替换与其他国家相似。

要点

  • 美国PCV引入后门诊IPD发病率下降94%,住院IPD下降79%。
  • 美国住院IPD中非PCV13型发病率增加超过2倍,门诊则下降51%。
  • 按住院状态分层后,美国住院IPD的PCV影响与血清型替换与其他国家相似。

核心结论

  • 按住院状态分层后,美国PCV项目对住院IPD的影响和血清型替换与其他国家相似。

研究设计与样本

  • 重新分析已发表汇总数据,比较不同国家PCV引入前后IPD发病率,分住院与门诊IPD分析。

主要发现

  • 英格兰与威尔士、芬兰、荷兰和魁北克/加拿大住院IPD比例持续高于80%,美国PCV引入前仅32%,PCV时代增至69%。
  • 美国门诊IPD发病率2015年较1998-99年下降94%,住院IPD下降79%。
  • 美国门诊非PCV13型IPD发病率估计下降51%,住院非PCV13型增加超过2倍。

临床怎么用

  • 评估PCV影响时应区分住院与门诊IPD,避免因就诊结构差异误判疫苗效果。

局限性

  • 基于已发表汇总数据的再分析,非原始个体数据研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed elsewhere. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in different countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era. In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998-99) was observed compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpatient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospitalised IPD in US when compared to other countries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Palmu AA, De Wals P, Toropainen M, et al. Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America. Vaccine. 2021. PMID: 33610373. doi:10.1016/j.vaccine.2021.01.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。